Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis

The Pharmacogenomics Journal volume 20, pages 553–562 (2020)Cite this article

Subjects

Abstract

Tacrolimus is an immunosuppressive drug widely used in kidney transplantation. Cytochrome P450 3A5 (CYP3A5) protein is involved in tacrolimus metabolism. Single nucleotide polymorphism in the CYP3A5 gene (6986A>G) results in alteration in metabolic activity of CYP3A5 protein which eventually affects the tacrolimus concentration. Patients with CYP3A5 expresser genotypes (A/A *1/*1 and A/G *1/*3) metabolize tacrolimus more rapidly than CYP3A5 nonexpressers (G/G *3/*3). We performed meta-analysis to estimate the effect of CYP3A5 polymorphism on the trough concentration–dose ratio (Co/D) and risk of renal allograft rejection with similar post-transplant periods and Asian vs. European populations. Our results showed that the tacrolimus Co/D ratio is significantly lower in CYP3A5 expresser group as compared with nonexpresser in Asian as well as in European populations at any post-transplant period (p < 0.00001). No significant association was found with renal allograft rejection episodes between expressers and nonexpressers in European populations (OR: 1.12; p = 0.47). Interestingly, Asian population (with expresser genotypes) and patients after 3 years post-transplantation (with expresser genotypes) have a higher risk of rejection (OR: 1.62; p < 0.05), (OR: 1.68; p < 0.05), respectively. This could be due to high prevalence of expresser genotypes in Asian population. Few tacrolimus-based studies are identified with long-term graft survival. There is a need to have more studies looking for long-term graft survival in expresser as well as no-expresser groups especially in Asian populations who have high frequency of CYP3A5 functional genotype.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Hamawy MM. Molecular actions of calcineurin inhibitors. Drug News Perspect. 2003;16:277–82.

    Article  CAS  Google Scholar 

  2. Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Storset E, Gustavsen MT, et al. High tacrolimus clearance is a risk factor for acute rejection in the early phase after renal transplantation. Transplantation. 2017;101:e273–e9.

    Article  CAS  Google Scholar 

  3. Huang CT, Shu KH, Ho HC, Wu MJ. Higher variability of tacrolimus trough level increases risk of acute rejection in kidney transplant recipients. Transplant Proc. 2016;48:1978–80.

    Article  CAS  Google Scholar 

  4. Miura M, Niioka T, Kagaya H, Saito M, Hayakari M, Habuchi T, et al. Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. J Clin Pharm Ther. 2011;36:208–16.

    Article  CAS  Google Scholar 

  5. Stratta P, Quaglia M, Cena T, Antoniotti R, Fenoglio R, Menegotto A, et al. The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol. 2012;68:671–80.

    Article  CAS  Google Scholar 

  6. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383–91.

    Article  CAS  Google Scholar 

  7. Tang HL, Xie HG, Yao Y, Hu YF. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers review. Pharmacogenetics Genom. 2011;21:713–20.

    Article  CAS  Google Scholar 

  8. Hendijani F, Azarpira N, Kaviani M. Effect of CYP3A5*1 expression on tacrolimus required dose for transplant pediatrics: a systematic review and meta-analysis. Pediatr Transplant. 2018;22:e13248.

  9. Rojas L, Neumann I, Herrero MJ, Boso V, Reig J, Poveda JL, et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015;15:38–48.

    Article  CAS  Google Scholar 

  10. Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. Pharmacogenetics Genom. 2012;22:642–5.

    Article  CAS  Google Scholar 

  11. Zong YP, Wang ZJ, Zhou WL, Zhou WM, Ma TL, Huang ZK, et al. Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies. World J Pediatr. 2017;13:421–6.

    Article  CAS  Google Scholar 

  12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  CAS  Google Scholar 

  13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.

    Article  CAS  Google Scholar 

  14. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1–48.

    Article  Google Scholar 

  15. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2014. http://www.R-project.org/.

  16. Flahault AD, Anglicheau, Loriot Marie-Anne, Thervet Eric, Pallet Nicolas. Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes. Pharmacogenomics. 2017;18:165–73.

    Article  CAS  Google Scholar 

  17. Maldonado AQ, Asempa T, Hudson S, Rebellato LM. Prevalence of CYP3A5 genomic variances and their impact on tacrolimus dosing requirements among kidney transplant recipients in Eastern North Carolina. Pharmacotherapy. 2017;37:1081–8.

    Article  CAS  Google Scholar 

  18. Nair SS, Sarasamma S, Gracious N, George J, Anish TS, Radhakrishnan R. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level. Exp Clin Transplant. 2015;13(Suppl 1):197–200.

    PubMed  Google Scholar 

  19. Ro H, Min SI, Yang J, Moon KC, Kim YS, Kim SJ, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit. 2012;34:680–5.

    Article  CAS  Google Scholar 

  20. Singh R, Srivastava A, Kapoor R, R KS, R DM. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renalallograft recipients of North India. Naunyn-Schmiedebergs Arch Pharmacol. 2009;380:169–77.

    Article  CAS  Google Scholar 

  21. Chen JS, Li LS, Cheng DR, Ji SM, Sun QQ, Cheng Z, et al. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. Transplant Proc. 2009;41:1557–61.

    Article  CAS  Google Scholar 

  22. Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit. 2010;32:394–404.

    Article  CAS  Google Scholar 

  23. Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol. 2008;103:546–52.

    Article  CAS  Google Scholar 

  24. Stegall MD, Cornell LD, Park WD, Smith BH, Cosio FG. Renal allograft histology at 10 years after transplantation in the tacrolimus era: evidence of pervasive chronic injury. Am J Transplant. 2018;18:180–8.

    Article  CAS  Google Scholar 

  25. Min SI, Kim SY, Ahn SH, Min SK, Kim SH, Kim YS, et al. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation. 2010;90:1394–400.

    Article  CAS  Google Scholar 

  26. Billing H, Hocker B, Fichtner A, van Damme-Lombaerts R, Friman S, Jaray J, et al. Single-nucleotide polymorphism of cyp3a5 impacts the exposure to tacrolimus in pediatric renal transplant recipients: a pharmacogenetic substudy of the TWIST Trial. Therapeutic Drug Monit. 2017;39:21–28.

    Article  CAS  Google Scholar 

  27. Almeida-Paulo GN, Dapia Garcia I, Lubomirov R, Borobia AM, Alonso-Sanchez NL, Espinosa L, et al. Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant. Pharmacogenomics J. 2018;18:180–6.

    Article  CAS  Google Scholar 

  28. Aouam K, Kolsi A, Kerkeni E, Ben Fredj N, Chaabane A, Monastiri K, et al. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. Pharmacogenomics. 2015;16:2045–54.

    Article  CAS  Google Scholar 

  29. Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Habuchi T, et al. Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation. Int J Mol Sci. 2015;16:1840–54.

    Article  CAS  Google Scholar 

  30. Han N, Ha S, Yun HY, Kim MG, Min SI, Ha J, et al. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin Pharm Toxicol. 2014;114:400–6.

    Article  CAS  Google Scholar 

  31. Coto E, Tavira B, Suarez-Alvarez B, Lopez-Larrea C, Diaz-Corte C, Ortega F, et al. Pharmacogenetics of tacrolimus: ready for clinical translation? Kidney Int Suppl. 2011;1:58–62.

    Article  CAS  Google Scholar 

  32. Zhang J, Zhang X, Liu L, Tong W. Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients. Transplant Proc. 2010;42:3459–64.

    Article  CAS  Google Scholar 

  33. Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit. 2009;31:187–97.

    Article  CAS  Google Scholar 

  34. Satoh S, Saito M, Inoue T, Kagaya H, Miura M, Inoue K, et al. CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2009;65:473–81.

    Article  CAS  Google Scholar 

  35. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation-DL. Am J Transplant. 2004;4:914–9.

    Article  CAS  Google Scholar 

  36. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation. 2003;76:1233–5.

    Article  CAS  Google Scholar 

  37. Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, et al. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep. 2010;62:1159–69.

    Article  CAS  Google Scholar 

  38. Kurzawski M, Dąbrowska J, Dziewanowski K, Domański L, Perużyńska M, Droździk M. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics. 2014;15:179–88.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a core grant to SIUT.

Author information

Authors and Affiliations

  1. Centre for Human Genetics and Molecular Medicine, Sindh Institute of Urology and Transplantation, Karachi, Pakistan

    Abdul Rafay Khan, Ali Raza, Sadaf Firasat & Aiysha Abid

Authors
  1. Abdul Rafay Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ali Raza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sadaf Firasat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aiysha Abid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aiysha Abid.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khan, A.R., Raza, A., Firasat, S. et al. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis. Pharmacogenomics J 20, 553–562 (2020). https://doi.org/10.1038/s41397-019-0144-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41397-019-0144-7

This article is cited by

Search

Advanced search

Quick links